VIDEO: Tezepelumab improves on-treatment response vs. placebo in severe asthma
Click Here to Manage Email Alerts
SAN FRANCISCO — In this video exclusive, Njira L. Lugogo, MD, details a new analysis of the NAVIGATOR study in which more patients with severe, uncontrolled asthma treated with tezepelumab achieved on-treatment clinical response vs. placebo.
In the new analysis, presented at the American Thoracic Society International Conference, nearly half of patients assigned tezepelumab (Tezspire, Amgen/AstraZeneca) achieved complete response to treatment across measures of asthma exacerbation reduction, asthma control, lung function and clinician assessment.
Lugogo is an associate professor of internal medicine, medical director of the Michigan Clinical Research Unit and director of the asthma program in the division of pulmonary and critical care medicine at the University of Michigan.
Watch the video for more.
References:
- Lugogo N, et al. Breakthroughs in Pediatric and Adult Asthma Clinical Trials. Presented at: American Thoracic Society International Conference; May 13-18, 2022; San Francisco (hybrid meeting).
- NAVIGATOR data show half of patients with severe, uncontrolled asthma improved with tezepelumab therapy. Published May 16, 2022. Accessed May 16, 2022.
- Lugogo N, et al. Am J Respir Crit Care Med. 2022;doi:10.1164/ajrccm-conference.2022.205.1.